United Therapeutics (UTHR) Preferred Stock Liabilities (2012 - 2019)

United Therapeutics has disclosed Preferred Stock Liabilities across 8 years of filings, most recently posting $8.4 million for Q2 2019.

• Preferred Stock Liabilities for Q2 2019 came in at $8.4 million, down 56.25% year-over-year; the trailing twelve-month figure through Jun 2019 was $8.4 million (down 56.25% YoY), and the FY2018 annual result was $19.2 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities came in at $8.4 million for Q2 2019 at United Therapeutics, down from $19.2 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $20.4 million in Q1 2015 to a low of $8.4 million in Q2 2019.
• The 5-year median for Preferred Stock Liabilities is $16.1 million (2015), against an average of $15.2 million.
• Across the five-year window, Preferred Stock Liabilities slumped 66.6% in 2015 and surged 76.15% in 2017, its largest moves.
• United Therapeutics' Preferred Stock Liabilities stood at $11.1 million in 2015, then declined by 1.8% to $10.9 million in 2016, then soared by 76.15% to $19.2 million in 2017, then changed by 0.0% to $19.2 million in 2018, then tumbled by 56.25% to $8.4 million in 2019.
• The last three Preferred Stock Liabilities figures came in at $8.4 million (Q2 2019), $19.2 million (Q1 2019), and $19.2 million (Q4 2018), per Business Quant data.